Dapagliflozin

Davis, Portia N.; Ndefo, Uche Anadu; Oliver, Ashley

doi:10.1177/0897190014566308

Cited by 4 publications

(1 citation statement)

References 22 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effective therapeutic agents are, therefore, needed to manage diabetes as well as to prevent diabetes-associated microvascular and macrovascular complications [2]. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel class of drugs effective in managing type 2 diabetes mellitus, both as monotherapy and combined with other agents [3]. One member of this class, dapagliflozin, is a highly selective, potent SGLT2i, first licensed for use in Pakistan in 2017 [4,5].…”

Section: Introductionmentioning

confidence: 99%

The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan

Kamin

Ishtiaq

Raashid

et al. 2020

Cureus

View full text Add to dashboard Cite

IntroductionDapagliflozin is a member of a novel class of drugs (sodium-glucose cotransporter-2 inhibitors) used to treat type 2 diabetes mellitus and licensed in Pakistan in 2017. This retrospective observational study evaluated the effects of dapagliflozin on glycated hemoglobin (HbA1c) concentrations in patients treated at endocrinology clinics in Islamabad, Pakistan. The secondary objectives included assessing the effects of dapagliflozin on weight reduction and blood pressure control and to determining its safety. MethodologyPatients with type 2 diabetes who were treated with dapagliflozin were identified by screening the electronic medical records at tertiary care hospitals in Islamabad. Data were collected at the first visit and at follow-up. Categorical variables were recorded as frequencies and percentages and compared by McNemar's tests, and continuous variables were recorded as means and standard deviations and compared by paired sample ttests. ResultsMean HbA1C concentration was significantly lower at follow-up than at the first visit (7.57%±0.98% vs. 9.07%±2.07%, respectively; p<0.001). Bodyweight (85.09±15.92 kg vs. 87.07±16.11 kg, respectively; p<0.001) and diastolic blood pressure (80.34±7.12 mmHg vs. 82.34±9.61 mmHg, respectively; p<0.001) were also significantly lower at follow-up than at the first visit, whereas systolic pressure showed a marginally significant reduction (123.5±16.57 mmHg vs. 126.83±19.97 mmHg, p=0.048). ConclusionThis first observational study of patients in Pakistan treated with dapagliflozin found that HbA1c concentration, weight, and blood pressure were reduced after initiation of dapagliflozin treatment.

show abstract

Section: Introductionmentioning

confidence: 99%